Cardiff Oncology, Inc. (XE7C.F)
| Previous close | 2.8950 |
| Open | 3.0700 |
| Bid | 3.0700 x 0 |
| Ask | 3.1300 x 0 |
| Day's range | 3.0700 - 3.0700 |
| 52-week range | 0.8670 - 5.5900 |
| Volume | |
| Avg. volume | 227 |
| Market cap | 140.645M |
| Beta (5Y monthly) | 1.97 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8700 |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 25.33 |
Simply Wall St.Cardiff Oncology First Quarter 2024 Earnings: Beats Expectations
Cardiff Oncology ( NASDAQ:CRDF ) First Quarter 2024 Results Key Financial Results Net loss: US$10.0m (loss narrowed by...
GlobeNewswireCardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated mCRC lead program - - In RAS wild-type mCRC, preclinical data presented at AACR demonstrated onvansertib’s antitumor activity both as a single agent and in combination, highlighting its broad activity across all mCRC - - In SCLC and ovarian cancer, preclinical data presented at AACR highlighted onvan
- GlobeNewswire
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
- Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the first quarter ended March 31, 2024 on Thursday, May 2 after the close of trading. Conference Call and Webcast Cardiff Oncology will host
